397 related articles for article (PubMed ID: 38175479)
21. Frontiers in antibiotic alternatives for
Phanchana M; Harnvoravongchai P; Wongkuna S; Phetruen T; Phothichaisri W; Panturat S; Pipatthana M; Charoensutthivarakul S; Chankhamhaengdecha S; Janvilisri T
World J Gastroenterol; 2021 Nov; 27(42):7210-7232. PubMed ID: 34876784
[No Abstract] [Full Text] [Related]
22. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
23. Candida gut colonization, yeast species distribution, and biofilm production in Clostridioides difficile infected patients: a comparison between three populations in two different time periods.
Brunetti G; Giuliani A; Navazio AS; Paradisi C; Raponi F; Conti LA; Raponi G
Braz J Microbiol; 2021 Dec; 52(4):1845-1852. PubMed ID: 34264501
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effect of Brazilian red propolis on planktonic and biofilm forms of Clostridioides difficile.
Costa CL; Azevedo CP; Quesada-Gómez C; Brito GAC; Regueira-Neto MDS; Guedes GMM; Rocha MFG; Sidrim JJC; Cordeiro RA; Carvalho CBM; Castelo-Branco DSCM
Anaerobe; 2021 Jun; 69():102322. PubMed ID: 33515722
[TBL] [Abstract][Full Text] [Related]
26. Emerging alternatives against Clostridioides difficile infection.
Romero-Rodríguez A; Martínez de la Peña C; Troncoso-Cotal S; Guzmán C; Sánchez S
Anaerobe; 2022 Dec; 78():102638. PubMed ID: 36210608
[TBL] [Abstract][Full Text] [Related]
27. Pathogenicity and virulence of
Buddle JE; Fagan RP
Virulence; 2023 Dec; 14(1):2150452. PubMed ID: 36419222
[No Abstract] [Full Text] [Related]
28. Fidaxomicin for the treatment of
Skinner AM; Scardina T; Kociolek LK
Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
[TBL] [Abstract][Full Text] [Related]
29. Outcome of relapsing Clostridium difficile infections do not correlate with virulence-, spore- and vegetative cell-associated phenotypes.
Plaza-Garrido Á; Miranda-Cárdenas C; Castro-Córdova P; Olguín-Araneda V; Cofré-Araneda G; Hernández-Rocha C; Carman R; Ibáñez P; Fawley WN; Wilcox MH; Gil F; Calderón IL; Fuentes JA; Guzmán-Durán AM; Alvarez-Lobos M; Paredes-Sabja D
Anaerobe; 2015 Dec; 36():30-8. PubMed ID: 26403333
[TBL] [Abstract][Full Text] [Related]
30. Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy.
Mehta SR; Yen EF
Transl Res; 2021 Apr; 230():197-207. PubMed ID: 33278650
[TBL] [Abstract][Full Text] [Related]
31. Gut microbiota in burned patients with Clostridioides difficile infection.
Shoaei P; Shojaei H; Siadat SD; Moshiri A; Vakili B; Yadegari S; Ataei B; Khorvash F
Burns; 2022 Aug; 48(5):1120-1129. PubMed ID: 34924229
[TBL] [Abstract][Full Text] [Related]
32. Revealing roles of S-layer protein (SlpA) in
Wang S; Courreges MC; Xu L; Gurung B; Berryman M; Gu T
Microbiol Spectr; 2024 Jun; 12(6):e0400523. PubMed ID: 38709045
[No Abstract] [Full Text] [Related]
33. Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids.
Winston JA; Rivera AJ; Cai J; Thanissery R; Montgomery SA; Patterson AD; Theriot CM
Infect Immun; 2020 May; 88(6):. PubMed ID: 32205405
[No Abstract] [Full Text] [Related]
34. Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
Steed DB; Wang T; Raheja D; Waldman AD; Babiker A; Dhere T; Kraft CS; Woodworth MH
mSphere; 2020 Oct; 5(5):. PubMed ID: 33055258
[TBL] [Abstract][Full Text] [Related]
35. The Gut Microbiota Is Associated with Clearance of Clostridium difficile Infection Independent of Adaptive Immunity.
Leslie JL; Vendrov KC; Jenior ML; Young VB
mSphere; 2019 Jan; 4(1):. PubMed ID: 30700514
[No Abstract] [Full Text] [Related]
36. Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin.
Darkoh C; Keita K; Odo C; Oyaro M; Brown EL; Arias CA; Hanson BM; DuPont HL
Clin Infect Dis; 2022 Jan; 74(1):120-126. PubMed ID: 35016207
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.
Sholeh M; Krutova M; Forouzesh M; Mironov S; Sadeghifard N; Molaeipour L; Maleki A; Kouhsari E
Antimicrob Resist Infect Control; 2020 Sep; 9(1):158. PubMed ID: 32977835
[TBL] [Abstract][Full Text] [Related]
38. Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile.
Phanchana M; Phetruen T; Harnvoravongchai P; Raksat P; Ounjai P; Chankhamhaengdecha S; Janvilisri T
Sci Rep; 2020 Apr; 10(1):6497. PubMed ID: 32300130
[TBL] [Abstract][Full Text] [Related]
39. Comparative biofilm-forming ability between
Morais MLGDS; Santos MGC; Costa CL; Martins CS; Leitão RFC; de Melo Pacífico D; Quesada-Gómez C; Castelo Branco D; Ferreira EO; Brito GAC
Front Cell Infect Microbiol; 2022; 12():1033698. PubMed ID: 36619751
[TBL] [Abstract][Full Text] [Related]
40. Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation.
Tubau-Juni N; Bassaganya-Riera J; Leber AJ; Alva SS; Hontecillas R
Inflamm Bowel Dis; 2024 Jan; 30(1):103-113. PubMed ID: 37436905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
